Educational, research-use-only content. This article summarizes published scientific literature for informational purposes only and is not medical advice. The compounds discussed are supplied strictly for in-vitro laboratory research and are not approved for human or veterinary use.
What is GDF-8 (myostatin)?
GDF-8, better known as myostatin, is a member of the TGF-β family that acts as a negative regulator of skeletal-muscle mass — in other words, it puts a brake on muscle growth. It is one of the most studied targets in muscle biology (Attie et al., 2012).
What the research describes
Because myostatin limits muscle growth, researchers have studied what happens when it is blocked. A clinical study of a decoy receptor (ACE-031) that binds myostatin and related factors reported measurable increases in lean body mass and muscle volume, illustrating myostatin’s role as a brake on muscle (Attie et al., 2012). This makes myostatin a key reference molecule in research on muscle-wasting conditions.
The limits of the current evidence
- Myostatin biology is well established, but therapeutic manipulation remains investigational, and no myostatin-targeting therapy of this kind is broadly approved.
- This material is for laboratory research use only.
References
According to PubMed:
- Attie KM, et al. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2012. doi:10.1002/mus.23539
